ERBB2 and cancer: Cancer cells with ERBB2 aberrations overexpress HER2 (human epidermal growth factor receptor 2) receptors, increasing ligand sensitivity and activating downstream pathways (e.g., the MAPK and PI3K-AKT pathways).